News | Heart Valve Technology | October 26, 2017

Henry Ford Hospital Cardiologist Receives National Award for Innovating Transcaval Heart Procedure

Health system performed 100th transcaval procedure in May

Henry Ford Hospital Cardiologist Receives National Award for Innovating Transcaval Heart Procedure

October 26, 2017 — The National Institutes of Health has awarded Detroit cardiologist Adam Greenbaum, M.D., for his pioneering work on the novel transcaval heart procedure.

Greenbaum, co-director of the Henry Ford Center for Structural Heart Disease, has received the prestigious 2017 Orloff Award from the NIH’s National Heart, Lung and Blood Institute. The NIH announced that Greenbaum and NIH Cardiovascular Intervention Program Senior Investigator Robert J. Lederman, M.D., were awarded for pioneering and proving the effectiveness of the transcaval procedure.

The unique procedure accesses the heart by temporarily connecting major blood vessels in the patient’s abdomen. The recognition comes as a 76-year-old metro Detroit man became the 100th patient to undergo the procedure at Henry Ford Hospital on May 11, 2017. Greenbaum performed the first human transcaval procedure in the world on July 3, 2013.

“The success of the 100th transcaval procedure at Henry Ford is truly gratifying, and the Orloff Award acknowledges the importance of our work,” said Greenbaum, who has spent years working with Lederman on new ways of accessing the heart. “The transcaval procedure provides an option for those patients who thought they had none – and for those doctors treating them.”

The Orloff Award recognizes outstanding achievements in science and the development of novel research tools in the previous year by NIH researchers and those working with them. The Orloff Science Awards are named in honor of Dr. Jack Orloff, a longtime member of the NHLBI intramural family and scientific director from 1974-1988.

A study published in November in the Journal of the American College of Cardiology showed the novel way to access the heart for transcatheter valve replacement has a 98 percent success rate.

“There were some doubters, so the reason we did this prospective trial was to prove that it could be done safely,” Greenbaum said.

Lederman developed the transcaval technique in a research setting at the NIH. He came to Henry Ford in July 2013 to observe the initial procedure and share his insights.

Since then, the procedure has been performed when the patients were either too sick for traditional open-heart surgery, or their anatomy – like small arteries — prevented the use of more traditional routes to the heart using a catheter.

The 100th patient, Hugh Lesner, had plaque build-up that made accessing his heart difficult through the traditional route. Lesner, a former union president and mill operator who retired from Great Lakes Steel after 36 ½ years, was out of the hospital the next day.

During transcaval valve replacement, a wire is guided into a leg and up through the femoral vein. An opening between the vein and artery is widened to the point of allowing a catheter to connect them, continue to the heart, and implant the new artificial aortic heart valve.

As the catheter is removed, a plug is inserted in the artery to close the hole made for the temporary connection of the two major blood vessels. Greenbaum and the Center for Structural Heart Disease team at Henry Ford Hospital are the most experienced team performing the procedure in the United States.

William O’Neill, M.D., medical director of Henry Ford’s Center for Structural Heart Disease, says the procedure could help more than 10,000 patients annually.

“The milestone brings a message of hope for other potential patients in Michigan and across the country,” said O’Neill.

For more information: www.henryfordhospital.com/structuralheart

Related Transcaval TAVR Content

VIDEO: Transcaval Access in TAVR Procedures

Study Deems Transcaval Valve Replacement Pioneered at Henry Ford Hospital Successful

First Transcaval Aortic Valve Replacement Performed in Europe

 

Related Content

Among high-risk, chronic, coronary patients who undergo angioplasty, there were no additional benefits from ticagrelor compared to the current standard of care clopidogrel. #AHA #AHA20 #AHA2020
News | Cath Lab | November 16, 2020
November 16, 2020 — The use of the more potent antiplatelet medication ticagrelor (Brilinta) was not superior to clop
A large subgroup analysis of the VOYAGER PAD randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes was consistent regardless of whether a DCD was used. #TCT2020 #TCTconnect
Feature | Cath Lab | October 18, 2020
October 18, 2020 – A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benef
A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin capped fibrous atheroma (TCFA). #TCTconnect #TCT2020

A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin cap fibro-atheroma (TCFA).

News | Cath Lab | October 18, 2020
October 18, 2020 – Data from the...
The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions. #TCT2-0

The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions.

Feature | Cath Lab | October 16, 2020
October 15, 2020 — Shockwave Medical's Intravascular Lithotripsy (IVL) system to treat severely calcified coronary ar
Videos | Cath Lab | October 16, 2020
This is an example pf the Shockwave Medical Intravascular Lithotripsy (IVL) catheter system designed to break up heav
Videos | Cath Lab | July 15, 2020
Richard Botto, CVT, RCSA, chief cardiovascular technologist, division of cardiology, cardiac cath lab, offers an over
Videos | Cath Lab | July 13, 2020
The Vieussens’ arterial ring (VAR) is a connection between the conus artery and the left anterior descending (LAD) co
News | Cath Lab | July 06, 2020
July 6, 2020 — Black patients who undergo percutaneous coronary intervention (PCI) are at an increased risk for major